|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ren J, Nie Y, Lv M, Shen S, Tang R, Xu Y,
Hou Y, Zhao S and Wang T: Estrogen upregulates MICA/B expression in
human non-small cell lung cancer through the regulation of ADAM17.
Cell Mol Immunol. 12:768–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gao L, Zhang H, Zhang B, Zhang L and Wang
C: Prognostic value of combination of preoperative platelet count
and mean platelet volume in patients with resectable non-small cell
lung cancer. Oncotarget. 8:15632–15641. 2017.PubMed/NCBI
|
|
4
|
Proto C, Imbimbo M, Gallucci R, Brissa A,
Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco
FG, et al: Epidermal growth factor receptor tyrosine kinase
inhibitors for the treatment of central nervous system metastases
from non-small cell lung cancer: The present and the future. Transl
Lung Cancer Res. 5:563–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nature Rev Drug Discov. 4:307–320.
2005. View
Article : Google Scholar
|
|
8
|
Gridelli C, Aapro M, Ardizzoni A, Balducci
L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F,
Rosell R, et al: Treatment of advanced non-small-cell lung cancer
in the elderly: Results of an international expert panel. J Clin
Oncol. 23:3125–3137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lindahl T: Instability and decay of the
primary structure of DNA. Nature. 362:709–715. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M and Wilson DM III: Human
apurinic/apyrimidinic endonuclease 1. Antioxid Redox Signal.
20:678–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barchiesi A, Wasilewski M, Chacinska A,
Tell G and Vascotto C: Mitochondrial translocation of APE1 relies
on the MIA pathway. Nucleic Acids Res. 43:5451–5464. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lo YL, Jou YS, Hsiao CF, Chang GC, Tsai
YH, Su WC, Chen KY, Chen YM, Huang MS, Hu CY, et al: A polymorphism
in the APE1 gene promoter is associated with lung cancer risk.
Cancer Epidemiol Biomarkers Prev. 18:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Woo J, Park H, Sung SH, Moon BI, Suh H and
Lim W: Prognostic value of human apurinic/apyrimidinic endonuclease
1 (APE1) expression in breast cancer. PLoS One. 9:e995282014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren T, Qing Y, Dai N, Li M, Qian C, Yang
Y, Cheng Y, Li Z, Zhang S, Zhong Z and Wang D:
Apurinic/apyrimidinic endonuclease 1 induced upregulation of
fibroblast growth factor 2 and its receptor 3 induces angiogenesis
in human osteosarcoma cells. Cancer Sci. 105:186–194. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang D, Xiang DB, Yang XQ, Chen LS, Li MX,
Zhong ZY and Zhang YS: APE1 overexpression is associated with
cisplatin resistance in non-small cell lung cancer and targeted
inhibition of APE1 enhances the activity of cisplatin in A549
cells. Lung Cancer. 66:298–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang S, He L, Dai N, Guan W, Shan J, Yang
X, Zhong Z, Qing Y, Jin F and Chen C: Serum APE1 as a predictive
marker for platinum-based chemotherapy of non-small cell lung
cancer patients. Oncotarget. 7:77482–77494. 2016.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mowers EE, Sharifi MN and Macleod KF:
Functions of autophagy in the tumor microenvironment and cancer
metastasis. FEBS J. 285:1751–1766. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun T, Liu H and Ming L: Multiple roles of
autophagy in the sorafenib resistance of hepatocellular carcinoma.
Cell Physiol Biochem. 44:716–727. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei MF, Chen MW, Chen KC, Lou PJ, Lin SY,
Hung SC, Hsiao M, Yao CJ and Shieh MJ: Autophagy promotes
resistance to photodynamic therapy-induced apoptosis selectively in
colorectal cancer stem-like cells. Autophagy. 10:1179–1192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sridhar S, Botbol Y, Macian F and Cuervo
AM: Autophagy and disease: Always two sides to a problem. J Pathol.
226:255–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boya P, Reggiori F and Codogno P: Emerging
regulation and functions of autophagy. Nat Cell Biol. 15:713–720.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jarauta V, Jaime P, Gonzalo O, de Miguel
D, Ramírez-Labrada A, Martínez-Lostao L, Anel A, Pardo J, Marzo I
and Naval J: Inhibition of autophagy with chloroquine potentiates
carfilzomib-induced apoptosis in myeloma cells in vitro and in
vivo. Cancer Lett. 382:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gewirtz DA: The four faces of autophagy:
Implications for cancer therapy. Cancer Res. 74:647–651. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Villa E, Proics E, Rubio-Patino C, Obba S,
Zunino B, Bossowski JP, Rozier RM, Chiche J, Mondragón L, Riley JS,
et al: Parkin-Independent mitophagy controls chemotherapeutic
response in cancer cells. Cell Rep. 20:2846–2859. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chourasia AH, Tracy K, Frankenberger C,
Boland ML, Sharifi MN, Drake LE, Sachleben JR, Asara JM, Locasale
JW, Karczmar GS and Macleod KF: Mitophagy defects arising from
BNip3 loss promote mammary tumor progression to metastasis. EMBO
Rep. 16:1145–1163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan C, Luo L, Guo CY, Goto S, Urata Y,
Shao JH and Li TS: Doxorubicin-induced mitophagy contributes to
drug resistance in cancer stem cells from HCT8 human colorectal
cancer cells. Cancer Lett. 388:34–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan C and Li TS: Dual role of mitophagy in
cancer drug resistance. Anticancer Res. 38:617–621. 2018.PubMed/NCBI
|
|
29
|
Kitada T, Asakawa S, Hattori N, Matsumine
H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y and Shimizu N:
Mutations in the parkin gene cause autosomal recessive juvenile
parkinsonism. Nature. 392:605–608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clark IE, Dodson MW, Jiang C, Cao JH, Huh
JR, Seol JH, Yoo SJ, Hay BA and Guo M: Drosophila pink1 is required
for mitochondrial function and interacts genetically with parkin.
Nature. 441:1162–1166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geisler S, Holmstrom KM, Skujat D, Fiesel
FC, Rothfuss OC, Kahle PJ and Springer W: PINK1/Parkin-mediated
mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biol.
12:119–131. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawajiri S, Saiki S, Sato S, Sato F,
Hatano T, Eguchi H and Hattori N: PINK1 is recruited to
mitochondria with parkin and associates with LC3 in mitophagy. FEBS
Lett. 584:1073–1079. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsuda N, Sato S, Shiba K, Okatsu K,
Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, et al:
PINK1 stabilized by mitochondrial depolarization recruits parkin to
damaged mitochondria and activates latent parkin for mitophagy. J
Cell Biol. 189:211–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Narendra DP, Jin SM, Tanaka A, Suen DF,
Gautier CA, Shen J, Cookson MR and Youle RJ: PINK1 is selectively
stabilized on impaired mitochondria to activate Parkin. PLoS Biol.
8:e10002982010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vives-Bauza C, Zhou C, Huang Y, Cui M, de
Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, et al:
PINK1-dependent recruitment of parkin to mitochondria in mitophagy.
Proc Natl Acad Sci USA. 107:378–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carroll RG, Hollville E and Martin SJ:
Parkin sensitizes toward apoptosis induced by mitochondrial
depolarization through promoting degradation of Mcl-1. Cell Rep.
9:1538–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou J, Li G, Zheng Y, Shen HM, Hu X, Ming
QL, Huang C, Li P and Gao N: A novel autophagy/mitophagy inhibitor
liensinine sensitizes breast cancer cells to chemotherapy through
DNM1L-mediated mitochondrial fission. Autophagy. 11:1259–1279.
2015. View Article : Google Scholar : PubMed/NCBI
|
